Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Q2 2024 Earnings Call Transcript August 1, 2024 4:30 PM ET

Company Participants

Brandi Roberts - Executive Vice President and Chief Financial Officer
Kevin Lind - President and Chief Executive Officer
Randall Kaye - Executive Vice President and Chief Medical Officer

Conference Call Participants

Laura Chico - Wedbush Securities
Joel Beatty - Baird
Gavin Clark-Gartner - Evercore
Kalpit Patel - B. Riley Securities
David Hoang - Citigroup
Yatin Suneja - Guggenheim Securities

Operator

Good afternoon, ladies and gentlemen, and welcome to the Longboard Pharmaceuticals Earnings and Corporate Update Call. As a reminder, this conference call is being recorded.

I would now like to turn the call over to Brandi Roberts, Longboard’s Chief Financial Officer. You may begin.

Brandi Roberts

Thank you and good afternoon everyone. Welcome to Longboards conference call and webcast where we'll be providing a corporate update including results from our LP659 single-ascending dose study.

Before we begin today, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company including, without limitation, statements about the potential of our product candidates, the anticipated timing and design of clinical trials, top line data, commercial opportunities, and financial guidance. These statements are subject to risks and uncertainties that could cause actual results to differ. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward looking statements are discussed in greater detail in our most recent reports filed with the SEC. Please note that these forward-looking statements reflect our opinions only as of the date of this call, and we undertake no obligation to revise or publicly release the results of any revisions to these forward-looking statements in light of new information or future events.

With that, I'll hand the call over to Kevin Lind, Longboard's President and CEO. Kevin?

Kevin Lind

Thanks Brandi, and thank you very much to everyone joining us today during what is a very exciting time for Longboard. I'm extremely proud of what we have accomplished in 2024 across the entire organization and portfolio. I'm going to start off by providing an update on our lead asset, Bexicaserincaserin, a highly selective and specific 5-HT2C receptor agonist, and then hand it over to Dr. Kaye to provide an update on LP659, and then Brandi will give an update on our financials before we open the call for Q&A.